Engineered Polymers & Ceramics M&A: 123 Deals and a Clear Flight to Specialists

Engineered polymers M&A 2026 activity remained robust in the first half of the year, with 123 transactions recorded across engineered polymers, technical ceramics and related segments — a step-up from roughly 90 transactions in H1 2025, driven primarily by a markedly higher share of private-equity activity.

At MP Corporate Finance, we track developments across materials, engineered parts and devices, extruded parts, medical components and devices, and technical ceramics. The first half of 2026 highlighted a clear investment priority: acquisitions that add specialist capabilities, strengthen customer relationships and create opportunities for long-term growth.

Engineered polymers M&A 2026: strategic buyers and private equity drive consolidation

Strategic buyers accounted for 60 transactions in H1 2026, while private-equity buyers contributed a further 49. Industrial groups continued to expand their capabilities and geographic reach, while financial investors pursued businesses with potential for platform development and further acquisitions.

Financial sponsors have been the primary driver of this year’s engineered polymers M&A 2026 step-up in deal volume, as buy-and-build platforms matured into serial acquirers. The activity spans both new platform investments and acquisitions that expand existing portfolio companies. Callista Private Equity’s acquisition of Helvoet Mobility and Equity’s investment in Sävjo Plastic illustrate platform investment activity, while IGS’s acquisition of ACH Solution and Elastofirm’s acquisition of SEALABLE Solutions demonstrate continued demand for complementary capabilities. Together, these transactions highlight the role of financial investors in building specialised manufacturing groups.

Materials and engineered parts and devices each recorded 38 transactions, followed by medical components and devices with 36. This analysis focuses on transactions involving only European companies.

The breadth of engineered polymers M&A 2026 activity reflects different routes to growth across the value chain. For some buyers, the priority is expanding a product portfolio or manufacturing footprint. For others, it is gaining access to specialist processes and applications that would take time to develop internally.

Specialist capabilities shape acquisition strategies

Selected transactions illustrate these priorities. Essentra’s acquisition of Boteco expanded its machine component offering, while KB Components’ acquisition of Rabugino strengthened its European moulding capacity. Haidlmair’s acquisition of TFM added CNC and moulding capabilities, and Röchling Industrial’s acquisition of Terbrack Kunststoff broadened its engineering plastics portfolio.

Other transactions demonstrate demand for application-specific expertise. Elastofirm’s acquisition of SEALABLE Solutions expanded its infrastructure sealing portfolio, while IGS’s acquisition of ACH Solution added medical silicone moulding capabilities. In technical ceramics, Groupe Mplus’s acquisition of Groupe Rubis-Precis brought together complementary micromechanics and ceramics expertise.

Together, these engineered polymers M&A 2026 transactions point to a market in which strategic fit matters. Buyers are seeking capabilities that complement their existing operations and strengthen their position in attractive end markets.

Specialist manufacturing expertise and a clear role in customers’ value chains remain central to the investment case.

Valuations reflect differences across the sector

Listed peer-group valuations show meaningful variation between segments. At midyear, median TEV/EBITDA multiples stood at 10.4x for materials and 10.1x for engineered parts and devices, compared with 6.8x for extruded parts, 9.8x for medical components and devices, and 15.6x for technical ceramics.

Operating profitability also varied. Median EBITDA margins reached 13.2% for engineered parts and devices, 16.9% for extruded parts, 19.6% for medical components and devices, and 19.0% for technical ceramics.

Dispersion within each engineered polymers M&A 2026 segment is wide. In materials, specialty-oriented names such as Borouge trade on richer multiples than diversified peers like BASF, Covestro or Lanxess. Among engineered parts and devices, differentiated specialists such as Dätwyler and SFS stand apart from broader contract manufacturers. In extruded parts, Trelleborg and Advanced Drainage command clear premiums over volume-exposed peers. In medical components and devices, West Pharmaceutical, Gerresheimer and Teleflex illustrate the valuation support that regulated, recurring-revenue positions still attract. And in technical ceramics, limited pure-play exposure continues to sustain premium multiples at Kyocera, Murata and Corning. The medians give a useful anchor; the dispersion is where the real transaction read-across sits.

These benchmarks provide context for assessing the market, but they do not translate directly into acquisition multiples. Individual transaction valuations depend on the quality of earnings, customer exposure, technical differentiation and the strategic value a business offers a particular buyer.

Deep dive: medical components and ceramics stand out

Medical components and devices combined growth with quality in H1 2026: 36 transactions, a 19.6% median EBITDA margin and continued demand underpinned by regulated end-markets. Multiples have normalised from pandemic-era peaks (9.8x LTM TEV/EBITDA versus 11.5x a year earlier), but the segment remains attractive to both strategic consolidators and sponsor platforms seeking defensible, recurring positions. IGS’s acquisition of ACH Solution is representative of the continued appetite for specialist capabilities such as medical silicone tooling.

Technical ceramics was the valuation outlier. Only three transactions were recorded, but listed multiples nearly doubled year-on-year to a median 15.6x TEV/EBITDA, with 19.0% EBITDA margins. The combination of thin deal flow, pull from semiconductor, EV and medical end-markets, and limited pure-play listed exposure continues to drive a scarcity premium. Groupe Mplus’s acquisition of Groupe Rubis-Precis shows that strategic buyers are willing to move early when a differentiated European asset becomes available.

Outlook: operational resilience and differentiation remain priorities

We expect consolidation to continue through the remainder of 2026 as buyers pursue scale, complementary technologies and access to resilient markets. Improving financing conditions and strong corporate balance sheets support activity, although inflation, interest rates and geopolitical uncertainty remain relevant to investment decisions.

Two external factors warrant close attention, without being treated as sector-wide tailwinds. The pending PFAS restrictions are already shaping diligence and target positioning in exposed applications such as sealing, fluoropolymers and medical silicones. European energy pricing continues to drive a divergence between commodity-exposed names and specialty players, with the latter better placed to defend margins. Neither factor applies evenly across the sector, but both are now visible in deal theses and should inform how a transaction is prepared.

Fakuma provided a timely setting for discussions about these priorities, connecting developments in plastics processing with the investment decisions facing manufacturers. For business owners and acquirers, the question is how new technologies and specialist capabilities can strengthen competitiveness and support future growth.

For owners considering their strategic options, demonstrating those strengths is essential. Sustainable margins, reliable customer relationships and a defensible technical position help establish a clear investment case. In a modest-growth environment, predictable earnings and operational resilience are likely to carry particular weight.

If you would like to discuss what the current M&A environment means for your business, we would be happy to share our perspective. Get in touch with our sector experts Sinan İkiışık and Markus Wildmoser.